The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance

Yajnavalka Banerjee; Angelo M Patti; Rosaria V Giglio; Marcello Ciaccio; Suhina Vichithran; Shemima Faisal; Anca Panta Stoian; Ali Abbas Rizvi; Manfredi Rizzo

doi:10.1016/j.jdiacomp.2023.108517

The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance

J Diabetes Complications. 2023 Aug;37(8):108517. doi: 10.1016/j.jdiacomp.2023.108517. Epub 2023 Jun 10.

Authors

Yajnavalka Banerjee¹, Angelo M Patti², Rosaria V Giglio³, Marcello Ciaccio³, Suhina Vichithran⁴, Shemima Faisal⁴, Anca Panta Stoian⁵, Ali Abbas Rizvi⁶, Manfredi Rizzo⁷

Affiliations

¹ Department of Basic Sciences, College of Medicine and Health Sciences, Mohammed Bin Rashid University (MBRU), Dubai, United Arab Emirates. Electronic address: Yajnavalka.Banerjee@mbru.ac.ae.
² Internal Medicine Unit, "Vittorio Emanuele II" Hospital, Castelvetrano, Trapani, Italy.
³ Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Laboratory Medicine, University of Palermo, Palermo, Italy; Department of Laboratory Medicine, University Hospital "P. Giaccone", Palermo, Italy.
⁴ Department of Basic Sciences, College of Medicine and Health Sciences, Mohammed Bin Rashid University (MBRU), Dubai, United Arab Emirates.
⁵ Department of Diabetes, Nutrition, and Metabolic Diseases, Carol Davila University of Medicine, Bucharest, Romania; "Prof. Dr.N.C.Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania.
⁶ Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
⁷ Department of Basic Sciences, College of Medicine and Health Sciences, Mohammed Bin Rashid University (MBRU), Dubai, United Arab Emirates; Department of Diabetes, Nutrition, and Metabolic Diseases, Carol Davila University of Medicine, Bucharest, Romania; "Prof. Dr.N.C.Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania; School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy.

PMID: 37329706
DOI: 10.1016/j.jdiacomp.2023.108517

Abstract

Dyslipidaemia plays a prominent role in the genesis of atherosclerotic plaque and the increased cardiovascular risk in diabetes. Macrophages readily take up atherogenic lipoproteins, transforming into foam cells and amplifying vascular damage in the presence of endothelial dysfunction. We discuss the importance of distinct lipoprotein subclasses in atherogenic diabetic dyslipidaemia as well as the effects of novel anti-diabetic agents on lipoprotein fractions and ultimately on cardiovascular risk prevention. In patients with diabetes, lipid abnormalities should be aggressively identified and treated in conjunction with therapeutical agents used to prevent cardiovascular disease. The use of drugs that improve diabetic dyslipidaemia plays a prominent role in conferring cardiovascular benefit in individuals with diabetes.

Keywords: Atherosclerosis; Innovative therapies; Management; Small dense lipoprotein.

Publication types

Review

MeSH terms

Atherosclerosis* / complications
Atherosclerosis* / prevention & control
Clinical Relevance
Diabetes Mellitus*
Dyslipidemias* / complications
Dyslipidemias* / drug therapy
Humans
Lipoproteins
Risk Factors

Substances

Lipoproteins